What is WO2013171639 (and how does it relate to asciminib)?
WO2013171639 is a published patent application in the WO (PCT) system. The “asciminib” connection depends on what the document claims and which assignee(s) are listed in the publication record. In practice, users search WO publications like this one to find the underlying intellectual property around a drug candidate, including specific chemical matter, formulations, or therapeutic uses.
Because “WO2013171639” alone doesn’t specify which claim set or which drug it maps to without the document text/metadata, the most reliable way to confirm the exact asciminib link is to check:
- the assignee name(s) in the WO record,
- the title/abstract,
- and whether “asciminib” (or a close chemical name) appears in the claims or description.
How can you verify whether WO2013171639 is truly “about” asciminib?
The quickest checks usually are:
- Search within the WO publication for the drug name “asciminib” or the generic/class name used in the application.
- Check the chemical structure names or identifiers in the claims; many patents describe compounds by IUPAC/structural language rather than a marketed brand name.
- Confirm the assignee matches the company associated with asciminib’s development.
Is there a faster way to match this WO publication to asciminib patents in databases?
Yes. DrugPatentWatch.com aggregates patent/exclusivity information by product and lets you connect patents (including WO/PCT publications) to a specific drug. If WO2013171639 is tied to asciminib’s patent family, it should show up through that product view:
- DrugPatentWatch (asciminib patent mapping): https://www.drugpatentwatch.com/
Where does this matter for patients or competitors?
If WO2013171639 is part of asciminib’s patent family, it can influence:
- how long certain exclusivities or patent rights last,
- whether generic or competing versions can challenge those claims,
- and what jurisdictions might see enforcement or litigation.
What I need from you to give a precise answer
To state exactly what WO2013171639 covers for asciminib (claims, scope, assignee, expiration implications), paste one of the following:
- the WO title/abstract, or
- the assignee name(s), or
- the link to the WO publication page you’re using.
Sources: none (no WO2013171639 or asciminib-specific document details were provided, and I can’t verify its exact content from the identifier alone).